Abstract Number: 2474 • 2019 ACR/ARP Annual Meeting
Impact of Multidomain Disease Presentations on Overall Disease Burden Among Patients with Psoriatic Arthritis: Results from the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry
Background/Purpose: Psoriatic arthritis (PsA) is a chronic inflammatory disease with heterogeneous presentations that may involve peripheral arthritis, axial disease, enthesitis, dactylitis, and psoriatic skin and…Abstract Number: 2475 • 2019 ACR/ARP Annual Meeting
Prevalence of Disease Domain Presentations Among Patients with Psoriatic Arthritis: Results from the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry
Background/Purpose: Psoriatic arthritis (PsA) is a heterogeneous, chronic inflammatory disease of the skin and musculoskeletal system. Six key domains of PsA have been identified to…Abstract Number: 2476 • 2019 ACR/ARP Annual Meeting
Side Effects of Methotrexate and TNFi: Differences in Tolerability Among Patients with PsA and RA
Background/Purpose: Methotrexate (MTX) is generally well tolerated in rheumatoid arthritis (RA) but little is known about the tolerability of MTX in psoriatic arthritis (PsA). One…Abstract Number: 2477 • 2019 ACR/ARP Annual Meeting
Burden of Disease at Treatment Initiation Among Biologic-Naïve Patients with Oligoarticular versus Polyarticular Psoriatic Arthritis in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry
Background/Purpose: Oligoarticular PsA accounts for ≈50% of PsA worldwide, but only a paucity of data describes disease burden among these patients. The Corrona PsA/SpA Registry,…Abstract Number: 2478 • 2019 ACR/ARP Annual Meeting
Enthesitis Frequency and Treatment Patterns in Patients with Psoriatic Arthritis in Europe and Japan
Background/Purpose: Enthesitis, a symptom commonly associated with psoriatic arthritis (PsA), negatively affects quality of life. Although enthesitis is routinely reported in randomized clinical trials of…Abstract Number: 2479 • 2019 ACR/ARP Annual Meeting
Unmet Treatment Needs in Patients with Psoriatic Arthritis
Background/Purpose: Despite significant advances in the treatment of psoriatic arthritis (PsA), disease control and remission remain a challenge. Research characterizing residual disease burden with current…Abstract Number: 2480 • 2019 ACR/ARP Annual Meeting
Opioid Use Surrounding Diagnosis of Inflammatory Arthritis
Background/Purpose: Although treatment of inflammatory arthritis (IA) has improved, opioid use among patients remains common. A study from Finland showed increases in opioid use leading…Abstract Number: 2481 • 2019 ACR/ARP Annual Meeting
Uveitis in 320 Patients with Psoriatic Arthritis. Epidemiology, Clinical Features and Biological Treatment: Study from a Single University Center
Background/Purpose: Uveitis is an extra articular manifestation of psoriatic arthritis (PsA). Uveitis may be more chronic Biological therapy, especially monoclonal TNF inhibitors, are useful to…Abstract Number: 2482 • 2019 ACR/ARP Annual Meeting
Differences and Similarities According to Gender in Patients with Psoriatic Arthritis Initiating Biological Therapy
Background/Purpose: Growing evidence has pointed gender as a key variable influencing clinical response to biological drugs in psoriatic arthritis(PsA). Although the reasons remain unclear, it…Abstract Number: 2483 • 2019 ACR/ARP Annual Meeting
Comparison Between Composite Activity Indices to Assess Clinical Response to Biological Therapy in Patients with Psoriatic Arthritis
Background/Purpose: Assessment of the disease in psoriatic arthritis (PsA) remains a clinical challenge. Hence, there is no agreement on which index best correlates with the…Abstract Number: 2484 • 2019 ACR/ARP Annual Meeting
Gender Influence on Treatment Effectiveness in Psoriatic Arthritis
Background/Purpose: Gender has been lately suggested as influential in the response to treatment with biological drugs in spondyloarthritis. However, data about the association between gender…Abstract Number: 2485 • 2019 ACR/ARP Annual Meeting
Red Cell Distribution Width Positively Correlates with Atherosclerotic Cardiovascular Disease Risk Score in Psoriatic Arthritis and Decreases with BDMARD Therapy
Background/Purpose: Red blood cell distribution width (RDW) is a parameter that measures variation in red blood cell size and volume. It is elevated when there…Abstract Number: 2486 • 2019 ACR/ARP Annual Meeting
Evaluation of Clinical and Functional Parameters by Joint Involvement and Remission in Psoriatic Arthritis
Background/Purpose: Disease activity of psoriatic arthritis (PsA) is affected by many parameters including joint, spinal and skin involvement, enthesitis, dactylitis and pain. According to disease…Abstract Number: 2487 • 2019 ACR/ARP Annual Meeting
Identification of Circulating MicroRNA Signatures in Patients with Psoriasis and Psoriatic Arthritis to Develop Novel Strategies for Early Diagnosis of a Bone and Joint Involvement
Background/Purpose: MicroRNAs (miRNAs) are small non-coding RNAs which are regulating physiologic and pathological processes. In numerous diseases specific miRNA signatures have been identified and can…Abstract Number: 2488 • 2019 ACR/ARP Annual Meeting
MDA Versus DAPSA: Applicability in a Real World
Background/Purpose: Background/Purpose: Psoriatic arthritis (PsA) is a progressive, chronic, and potentially irreversible inflammatory disorder. Systematic clinical follow-up of PsA patients is necessary to maintain and…
ACR Meeting Abstracts